{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:13:28Z","timestamp":1760141608749,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejso.2024.108263","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:56:49Z","timestamp":1709931409000},"page":"108263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0524-6213","authenticated-orcid":false,"given":"Pablo","family":"Padilla-Iserte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Iv\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Muruzabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3303-3224","authenticated-orcid":false,"given":"Rafael","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6451-1817","authenticated-orcid":false,"given":"Berta","family":"D\u00edaz-Feijoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-1752","authenticated-orcid":false,"given":"Sara","family":"Iacoponi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Garc\u00eda-Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8426-262X","authenticated-orcid":false,"given":"Jes\u00fas","family":"Utrilla-Layna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-5590","authenticated-orcid":false,"given":"Antonio","family":"Gil-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7535-057X","authenticated-orcid":false,"given":"Anna","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Gilabert-Estell\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-0873","authenticated-orcid":false,"given":"Cristina","family":"Mart\u00ednez Canto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-4985","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Tejerizo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Lago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-1688","authenticated-orcid":false,"given":"Jos\u00e9 Miguel","family":"C\u00e1rdenas-Rebollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejso.2024.108263_bib1","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.ejso.2024.108263_bib2","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ejso.2024.108263_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ejso.2024.108263_bib4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejso.2024.108263_bib5","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology\/gynecologic oncology group study","volume":"37","author":"Walker","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"volume":"vol. 1","year":"2023","key":"10.1016\/j.ejso.2024.108263_bib6"},{"issue":"3","key":"10.1016\/j.ejso.2024.108263_bib7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2024.108263_bib8","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/bjc.2013.70","article-title":"BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study","volume":"108","author":"Lesnock","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2024.108263_bib9","unstructured":"Regulation (EU) 2016\/679 of the European Parliament (General Data Protection Regulation) https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32016R0679&from=EN."},{"issue":"21","key":"10.1016\/j.ejso.2024.108263_bib10","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2024.108263_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2007.11.004","article-title":"Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer","volume":"108","author":"Salani","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2024.108263_bib12","first-page":"CD005340","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","volume":"2016","author":"Jaaback","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ejso.2024.108263_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"10.1016\/j.ejso.2024.108263_bib14","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/IGC.0b013e31821ee777","article-title":"Feasibility of a modified outpatient regimen of intravenous\/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study","volume":"21","author":"Oaknin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2024.108263_bib15","unstructured":"Eastern Cooperative Oncology Group (ECOG) Performance Status Scale. ECOG-ACRIN Cancer Research Group. https:\/\/ecog-acrin.org\/resources\/ecog-performance-status\/."},{"issue":"1","key":"10.1016\/j.ejso.2024.108263_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2010.09.010","article-title":"Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment","volume":"120","author":"Aletti","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2024.108263_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2024.108263_bib18","unstructured":"NCI Common Terminology Criteria for Adverse Events (CTCAE) 5.0 version. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"issue":"7172","key":"10.1016\/j.ejso.2024.108263_bib19","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","article-title":"Survival probabilities (the Kaplan-Meier method)","volume":"317","author":"Bland","year":"1998","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ejso.2024.108263_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/biostatistics\/kxr014","article-title":"A\u00a0multivariate logistic regression","volume":"13","author":"Nikoloulopoulos","year":"2012","journal-title":"Biostatistics"},{"issue":"3","key":"10.1016\/j.ejso.2024.108263_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2018.10.003","article-title":"Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer","volume":"151","author":"Naumann","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2024.108263_bib22","first-page":"453","article-title":"History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications","volume":"4","author":"Muggia","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"5","key":"10.1016\/j.ejso.2024.108263_bib23","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1245\/s10434-013-3277-y","article-title":"Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin","volume":"21","author":"Kwa","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2024.108263_bib24","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2024.108263_bib25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ygyno.2021.01.037","article-title":"Post hoc analyses of GOG 9923: does BRCA status affect toxicities? An NRG oncology study","volume":"161","author":"Gillen","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2024.108263_bib26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jpedsurg.2019.09.013","article-title":"Dermal securement of port catheters in obese patients","volume":"55","author":"Rothenberg","year":"2020","journal-title":"J\u00a0Pediatr Surg"},{"issue":"26","key":"10.1016\/j.ejso.2024.108263_bib27","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.ejso.2024.108263_bib28","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl_8","key":"10.1016\/j.ejso.2024.108263_bib29","doi-asserted-by":"crossref","first-page":"viii40","DOI":"10.1093\/annonc\/mdx451","article-title":"Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?","volume":"28","author":"Monk","year":"2017","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.ejso.2024.108263_bib30","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.19.00671","article-title":"Role of intraperitoneal therapy in the initial management of ovarian cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108263_bib31","article-title":"Mirvetuximab soravtansine-gynx: first antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer","author":"Bogani","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"23","key":"10.1016\/j.ejso.2024.108263_bib32","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in fr\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ejso.2024.108263_bib33","first-page":"CD015048","article-title":"Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery","volume":"9","author":"Bryant","year":"2022","journal-title":"Cochrane Database Syst Rev"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324003159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324003159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:56:02Z","timestamp":1760061362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798324003159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0748798324003159"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108263","relation":{},"ISSN":["0748-7983"],"issn-type":[{"type":"print","value":"0748-7983"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108263"}}